SOST and osteoporosis: The painstaking study of these rare disorders led to recognition of sclerostin’s crucial repressive role in bone formation; its inhibition is currently being investigated in the treatment of osteoporosis in randomised clinical trials and may represent a paradigm shift in osteoporosis care in the near future (21).